H

Hansoh Pharmaceutical Group Company Ltd
HKEX:3692

Watchlist Manager
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Watchlist
Price: 18.52 HKD 1.42% Market Closed
Market Cap: 109.9B HKD
Have any thoughts about
Hansoh Pharmaceutical Group Company Ltd?
Write Note

Hansoh Pharmaceutical Group Company Ltd
Other Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Hansoh Pharmaceutical Group Company Ltd
Other Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Other Current Assets
ÂĄ129.8m
CAGR 3-Years
30%
CAGR 5-Years
28%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Other Current Assets
ÂĄ357.3m
CAGR 3-Years
-54%
CAGR 5-Years
-7%
CAGR 10-Years
24%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Other Current Assets
ÂĄ1.8B
CAGR 3-Years
13%
CAGR 5-Years
23%
CAGR 10-Years
24%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Other Current Assets
ÂĄ1B
CAGR 3-Years
-34%
CAGR 5-Years
5%
CAGR 10-Years
10%
C
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
Other Current Assets
ÂĄ59m
CAGR 3-Years
12%
CAGR 5-Years
6%
CAGR 10-Years
N/A
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Other Current Assets
ÂĄ70.3m
CAGR 3-Years
58%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Hansoh Pharmaceutical Group Company Ltd
Glance View

Market Cap
109.9B HKD
Industry
Pharmaceuticals

Hansoh Pharmaceutical Group Company Ltd., founded in 1995 and headquartered in Jiangsu, China, has rapidly evolved into one of the leading biopharmaceutical enterprises in the country. With a robust portfolio that spans biologics, small molecule drugs, and innovative therapies, Hansoh has carved a niche for itself by focusing on high-demand therapeutic areas such as oncology, central nervous system disorders, and autoimmune diseases. The company thrives on its commitment to research and development, partnering with academic institutions and international firms to drive innovation, which is pivotal in a competitive industry characterized by rapid technological advancements. Investors will find comfort in Hansoh's strong growth trajectory, marked by impressive revenue increases and a strategic intent to expand its footprint both domestically and globally. As the Chinese healthcare market continues to burgeon, driven by an aging population and evolving consumer demands, Hansoh Pharmaceutical is well-positioned to capitalize on these trends. Its recent listings on major global stock exchanges signal its ambition to attract international investors and strengthen its balance sheet for future endeavors. The company's strategic initiatives aim to diversify its product offerings and improve access to its innovative drugs, setting it apart from its competitors. With a management team that emphasizes prudent decision-making and value creation—echoing the principles of investment legends like Warren Buffett and Charlie Munger—Hansoh is not just a company; it is a growing story of success in the burgeoning pharmaceutical landscape that promises to deliver sustained value for its shareholders in the years to come.

Intrinsic Value
15.76 HKD
Overvaluation 15%
Intrinsic Value
Price
H

See Also

What is Hansoh Pharmaceutical Group Company Ltd's Other Current Assets?
Other Current Assets
129.8m CNY

Based on the financial report for Dec 31, 2023, Hansoh Pharmaceutical Group Company Ltd's Other Current Assets amounts to 129.8m CNY.

What is Hansoh Pharmaceutical Group Company Ltd's Other Current Assets growth rate?
Other Current Assets CAGR 5Y
28%

Over the last year, the Other Current Assets growth was 51%. The average annual Other Current Assets growth rates for Hansoh Pharmaceutical Group Company Ltd have been 30% over the past three years , 28% over the past five years .

Back to Top